Standard BioTools Q4 rev $23.8M (-4% YoY); FY2025 rev $85.3M (-6%); guides FY2026 $80-85M

STANDARD BIOTOOLS INC.

2025-FY EPS reported -$0.20 revenue$85,331,000

Q4 2025 net income from continuing ops $13.9M (includes $38.4M deferred tax release) vs net loss $27.2M YoY.
Full-year 2025 net loss $58.8M vs $90.9M; adjusted EBITDA loss $62.6M vs $64.2M.
FY2026 revenue guidance $80-85M; company expects seasonality similar to prior years.
Cash and investments from continuing ops $210.7M at Dec 31, 2025; ~$550M after SomaLogic close on Jan 30, 2026.
Approximately $1 billion in U.S. federal NOL carryforwards available; usage may be limited.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.